Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FWD 1509

Next Previous
X
Search
Drug Profile

FWD 1509

Alternative Names: FWD 1509 MsOH; FWD-1509

Latest Information Update: 15 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Forward Pharmaceutical
  • Developer Shenzhen Forward Pharmaceutical; WuXi Clinical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 23 Aug 2021 Phase-I/II clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT05068024)
  • 19 Aug 2021 CDE of the National Food and Drug Administration of China approves FWD 1509 for clinical use for the treatment of Non-small cell lung cancer in China
  • 19 Aug 2021 Shenzhen Forward Pharmaceutical plans a phase I trial for Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top